<p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 获取免费报告) 的股价在周四的交易中达到了新的 52 周高点。该公司的股价最高达到 16.60 美元，最后交易价格为 16.2420 美元，成交量为 210470 股。该股票此前收盘价为 15.36 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师最近对该股票发表了看法。巴克莱在 12 月 8 日的研究报告中开始覆盖 Phathom Pharmaceuticals 的股票。他们给予该公司的 “持平” 评级，并设定了 16.00 美元的目标价。雷蒙德·詹姆斯金融在 12 月 11 日的研究报告中开始覆盖 Phathom Pharmaceuticals 的股票。他们给予该股票 “强力买入” 评级，并设定了 28.00 美元的目标价。华尔街 Zen 在 10 月 18 日的研究报告中将 Phathom Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 10 月 31 日的研究报告中将 Phathom Pharmaceuticals 的目标价从 20.00 美元上调至 26.00 美元，并给予该公司 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Phathom Pharmaceuticals 的 “卖出（d-）” 评级。有两位分析师给予该股票 “强力买入” 评级，四位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Phathom Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为 21.00 美元。</p>
<p><strong>阅读我们关于 Phathom Pharmaceuticals 的最新研究报告</strong></p>
<h2>Phathom Pharmaceuticals 上涨 3.6%</h2>
<p>该公司的 50 日移动平均线为 14.09 美元，200 日移动平均线为 11.48 美元。该公司的市值为 11.3 亿美元，市盈率为-4.16，贝塔值为 0.43。</p>
<p>Phathom Pharmaceuticals (NASDAQ:PHAT - 获取免费报告) 最近在 10 月 30 日公布了季度财报。该公司报告季度每股收益为（0.15 美元），超出分析师共识预期的（0.30 美元）0.15 美元。该公司在本季度的收入为 4950 万美元，而分析师预期为 4703 万美元。作为一个整体，研究分析师预测 Phathom Pharmaceuticals, Inc.在本年度将发布-4.78 美元的每股收益。</p>
<h2>机构资金流入和流出</h2>
<p>一些大型投资者最近对该公司的持仓进行了调整。Jones Financial Companies Lllp 在第三季度将其在 Phathom Pharmaceuticals 的持股增加了 442.6%。Jones Financial Companies Lllp 目前拥有 2523 股该公司的股票，价值 30000 美元，此前在上个季度增持了 2058 股。雷蒙德·詹姆斯金融在第二季度购买了 Phathom Pharmaceuticals 的新股份，价值约 30000 美元。Ameritas Investment Partners Inc.在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 39.3%。Ameritas Investment Partners Inc.目前拥有 4311 股该公司的股票，价值 41000 美元，此前在上个季度增持了 1216 股。法国巴黎银行金融市场在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 71.9%。法国巴黎银行金融市场目前拥有 5072 股该公司的股票，价值 49000 美元，此前在上个季度增持了 2122 股。最后，Tower Research Capital LLC TRC 在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 58.3%。Tower Research Capital LLC TRC 目前拥有 5710 股该公司的股票，价值 55000 美元，此前在上个季度增持了 2102 股。99.01% 的股票由机构投资者持有。</p>
<h2>Phathom Pharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Phathom Pharmaceuticals, Inc.是一家生物制药公司，专注于开发和商业化治疗胃肠疾病的药物。该公司在美国、欧洲和加拿大拥有一种研究性钾竞争性酸阻滞剂（P-CAB）的权利，该药物可以阻止胃酸分泌。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Phathom Pharmaceuticals</li>
<li>最大的股票亏损者 - 今日最大百分比下跌者</li>
<li>3 只便宜的分红股票，可以战胜通货膨胀并支付你等待的费用</li>
<li>投资石油股票的方式和原因</li>
<li>3 只新年决议股票，可能在 2026 年反弹</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>大麻股票即将反转：幻想还是机会？</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Phathom Pharmaceuticals 吗？</h2>
<p>在你考虑 Phathom Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Phathom Pharmaceuticals 并不在名单上。</p>
<p>虽然 Phathom Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PHAT

<p>Phathom Pharmaceuticals（纳斯达克代码：PHAT）达到了新的 52 周高点 16.60 美元，收盘价为 16.2420 美元。分析师的评级不一，有些给予 “强烈买入” 和 “买入” 评级，而另一些则建议 “持有” 或 “卖出”。该公司报告了超出预期的上一季度收益。机构投资者对该股票表现出更高的兴趣。Phathom 专注于胃肠疾病的治疗，市值为 11.3 亿美元</p>

<p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report)'s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $16.60 and last traded at $16.2420, with a volume of 210470 shares trading hands. The stock had previously closed at $15.36.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 获取免费报告) 的股价在周四的交易中达到了新的 52 周高点。该公司的股价最高达到 16.60 美元，最后交易价格为 16.2420 美元，成交量为 210470 股。该股票此前收盘价为 15.36 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have recently weighed in on the stock. Barclays assumed coverage on shares of Phathom Pharmaceuticals in a research report on Monday, December 8th. They set an &#34;equal weight&#34; rating and a $16.00 price objective for the company. Raymond James Financial assumed coverage on shares of Phathom Pharmaceuticals in a research report on Thursday, December 11th. They set a &#34;strong-buy&#34; rating and a $28.00 price target on the stock. Wall Street Zen raised Phathom Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, October 18th. HC Wainwright boosted their price objective on Phathom Pharmaceuticals from $20.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Phathom Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $21.00.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了看法。巴克莱在 12 月 8 日的研究报告中开始覆盖 Phathom Pharmaceuticals 的股票。他们给予该公司的 “持平” 评级，并设定了 16.00 美元的目标价。雷蒙德·詹姆斯金融在 12 月 11 日的研究报告中开始覆盖 Phathom Pharmaceuticals 的股票。他们给予该股票 “强力买入” 评级，并设定了 28.00 美元的目标价。华尔街 Zen 在 10 月 18 日的研究报告中将 Phathom Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。HC Wainwright 在 10 月 31 日的研究报告中将 Phathom Pharmaceuticals 的目标价从 20.00 美元上调至 26.00 美元，并给予该公司 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Phathom Pharmaceuticals 的 “卖出（d-）” 评级。有两位分析师给予该股票 “强力买入” 评级，四位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，Phathom Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为 21.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on Phathom Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Phathom Pharmaceuticals 的最新研究报告</strong></p>
</div><h2>Phathom Pharmaceuticals Trading Up 3.6%</h2>
<div class="lb-trans"><h2>Phathom Pharmaceuticals 上涨 3.6%</h2>
</div><p>The business has a 50-day moving average of $14.09 and a 200 day moving average of $11.48. The firm has a market capitalization of $1.13 billion, a P/E ratio of -4.16 and a beta of 0.43.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 14.09 美元，200 日移动平均线为 11.48 美元。该公司的市值为 11.3 亿美元，市盈率为-4.16，贝塔值为 0.43。</p>
</div><p>Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.15. The firm had revenue of $49.50 million during the quarter, compared to analyst estimates of $47.03 million. As a group, research analysts forecast that Phathom Pharmaceuticals, Inc. will post -4.78 EPS for the current year.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals (NASDAQ:PHAT - 获取免费报告) 最近在 10 月 30 日公布了季度财报。该公司报告季度每股收益为（0.15 美元），超出分析师共识预期的（0.30 美元）0.15 美元。该公司在本季度的收入为 4950 万美元，而分析师预期为 4703 万美元。作为一个整体，研究分析师预测 Phathom Pharmaceuticals, Inc.在本年度将发布-4.78 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of large investors have recently made changes to their positions in the business. Jones Financial Companies Lllp raised its holdings in shares of Phathom Pharmaceuticals by 442.6% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company's stock worth $30,000 after acquiring an additional 2,058 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Phathom Pharmaceuticals during the 2nd quarter worth approximately $30,000. Ameritas Investment Partners Inc. increased its holdings in Phathom Pharmaceuticals by 39.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company's stock worth $41,000 after purchasing an additional 1,216 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Phathom Pharmaceuticals by 71.9% in the second quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company's stock worth $49,000 after purchasing an additional 2,122 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Phathom Pharmaceuticals by 58.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company's stock valued at $55,000 after purchasing an additional 2,102 shares in the last quarter. 99.01% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些大型投资者最近对该公司的持仓进行了调整。Jones Financial Companies Lllp 在第三季度将其在 Phathom Pharmaceuticals 的持股增加了 442.6%。Jones Financial Companies Lllp 目前拥有 2523 股该公司的股票，价值 30000 美元，此前在上个季度增持了 2058 股。雷蒙德·詹姆斯金融在第二季度购买了 Phathom Pharmaceuticals 的新股份，价值约 30000 美元。Ameritas Investment Partners Inc.在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 39.3%。Ameritas Investment Partners Inc.目前拥有 4311 股该公司的股票，价值 41000 美元，此前在上个季度增持了 1216 股。法国巴黎银行金融市场在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 71.9%。法国巴黎银行金融市场目前拥有 5072 股该公司的股票，价值 49000 美元，此前在上个季度增持了 2122 股。最后，Tower Research Capital LLC TRC 在第二季度将其在 Phathom Pharmaceuticals 的持股增加了 58.3%。Tower Research Capital LLC TRC 目前拥有 5710 股该公司的股票，价值 55000 美元，此前在上个季度增持了 2102 股。99.01% 的股票由机构投资者持有。</p>
</div><h2>Phathom Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Phathom Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals, Inc.是一家生物制药公司，专注于开发和商业化治疗胃肠疾病的药物。该公司在美国、欧洲和加拿大拥有一种研究性钾竞争性酸阻滞剂（P-CAB）的权利，该药物可以阻止胃酸分泌。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Phathom Pharmaceuticals</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>3 Cheap Dividend Stocks That Can Beat Inflation and Pay You to Wait</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>3 New Year’s Resolution Stocks That Could Turn Around in 2026</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Phathom Pharmaceuticals</li>
<li>最大的股票亏损者 - 今日最大百分比下跌者</li>
<li>3 只便宜的分红股票，可以战胜通货膨胀并支付你等待的费用</li>
<li>投资石油股票的方式和原因</li>
<li>3 只新年决议股票，可能在 2026 年反弹</li>
<li>FAANG 股票是什么，它们是好的投资吗？</li>
<li>大麻股票即将反转：幻想还是机会？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Phathom Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Phathom Pharmaceuticals 吗？</h2>
</div><p>Before you consider Phathom Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Phathom Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Phathom Pharmaceuticals 并不在名单上。</p>
</div><p>While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Phathom Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Phathom Pharmaceuticals（NASDAQ:PHAT）创下一年新高 - 接下来会如何发展？